Investigational drug for genetic form of ALS improves disease’s molecular signs

An international phase 3 clinical trial for a rare, inherited form of ALS showed that an investigational drug, known as tofersen, reduced molecular signs of disease, but at six months did not improve motor control and muscle strength. However, the researchers found evidence that longer-term use of the drug may help stabilize muscle strength and control.